Sarepta Therapeutics, Inc.

Sarepta Therapeutics develops gene-therapy and RNA-based therapies for Duchenne muscular dystrophy (Elevidys, Exondys 51, others) — a franchise with genuine clinical impact but ongoing safety and manufacturing overhangs. Down 22% over the past year with revenue now going negative YoY, entering Aug 5 earnings with real credibility questions.

Where things stand:

• The revenue turn is meaningful: Q1 revenue $731M (-1.9% YoY) with 62% gross margin and near-breakeven operating margin — after years of growth, negative revenue growth is the exact signal that suggests Elevidys ramp has hit a wall (either safety-driven adoption slowdown or center authorization plateauing).
• Investor litigation is now on the tape: reported Johnson Fistel investor investigation (July 13) — these follow every stock down 25%+ but are worth pricing in as a settlement-risk overhang; combined with X community members flagging that Sarepta's own slide-deck citations don't support the title/subtitles about TfR1 receptor availability, credibility is a real question.
• The Peyton's Project non-ambulatory framing is a legitimate positive: Elevidys still gives hope for non-ambulatory kids per patient-family accounts — this is the real durable clinical impact that eventually reasserts on the tape, but Wall Street is currently focused on the near-term revenue trajectory.

Cooling with revenue decel and credibility questions — Aug 5 is the trigger. A revenue beat plus Elevidys authorization data and clean safety commentary breaks toward $22+; a soft print or another safety signal extends the pullback to $12.